Association of core-binding factor β with the malignant phenotype of prostate and ovarian cancer cells

Journal of Cellular Physiology

Volumn 225, Issue 3, 2010, Pages 875-887

  Davis, J Nathan ^a   Rogers, Donna ^a   Adams, Lisa ^b   Yong, Thomas ^b   Jung, Jette S ^a   Cheng, Bing ^a   Fennell, Katie ^a   Borazanci, Erkut ^b   Moustafa, Yara W ^a   Sun, Amanda ^b   Shi, Runhua ^b   Glass, Jonathan ^b   Mathis, J Michael ^a   Williams, B Jill ^b   Meyers, Shari ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Louisiana State University School of Medicine Shreveport   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORE BINDING FACTOR BETA; DNA BINDING PROTEIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HETERODIMER; LENTIVIRUS VECTOR; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR RUNX; CBFB PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES FLUID; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; FEMALE; GENE CONTROL; GENE EXPRESSION PROFILING; HOMEOSTASIS; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SOLID TUMOR; STEM CELL; TUMOR XENOGRAFT; ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; CELL PROLIFERATION; CELL STRAIN 3T3; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; METABOLISM; MOUSE MUTANT; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; RNA INTERFERENCE; TIME; TUMOR CELL LINE; TUMOR VOLUME;

MUS;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CORE BINDING FACTOR BETA SUBUNIT; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MICE; MICE, NUDE; MICE, SCID; NEOPLASM TRANSPLANTATION; NIH 3T3 CELLS; PHENOTYPE; PROSTATIC NEOPLASMS; RNA INTERFERENCE; TIME FACTORS; TRANSFECTION; TUMOR BURDEN;

EID: 77957733190     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22298     Document Type: Article

References (59)

1. Adya N, Stacy T, Speck NA, Liu PP. 1998. The leukemic protein core binding factor beta (CBFbeta)-smooth-muscle myosin heavy chain sequesters CBFalpha2 into cytoskeletal filaments and aggregates. Mol Cell Biol 18: 7432-7443.
2. Adya N, Castilla LH, Liu PP. 2000. Function of CBFbeta/Bro proteins. Semin Cell Dev Biol 11: 361-368.
3. Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, van Wijnen AJ, Stein JL, Languino LR, Altieri DC, Pratap J, Keller E, Stein GS, Lian JB. 2009. Runx2 association with progression of prostate cancer in patients: Mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 29: 811-821.
4. Berx G, van Roy F. 2009. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol 1: a003129.
5. Blyth K, Cameron ER, Neil JC. 2005. The RUNX genes: Gain or loss of function in cancer. Nat Rev Cancer 5: 376-387.
6. Brubaker KD, Vessella RL, Brown LG, Corey E. 2003. Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate 56: 13-22.
7. Buijs A, Poddighe P, van Wijk R, van Solinge W, Borst E, Verdonck L, Hagenbeek A, Pearson P, Lokhorst H. 2001. A novel CBFA2 single-nucleotide mutation in familial platelet disorder with propensity to develop myeloid malignancies. Blood 98: 2856-2858.
8. Cifone MA. 1982. In vitro growth characteristics associated with benign and metastatic variants of tumor cells. Cancer Metastasis Rev 1: 335-347.
9. Cockrell AS, Kafri T. 2007. Gene delivery by lentivirus vectors. Mol Biotechnol 36: 184-204.
10. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. 1997. Osf2/Cbfa1: A transcriptional activator of osteoblast differentiation. Cell 89: 747-754.
11. Edgar R, Domrachev M, Lash AE. 2002. Gene expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: 201-210.
12. Fowler M, Borazanci E, McGhee L, Pylant SW, Williams BJ, Glass J, Davis JN, Meyers S. 2006. RUNX1 (AML-1) and RUNX2 (AML-3) cooperate with prostate-derived Ets factor to activate transcription from the PSA upstream regulatory region. J Cell Biochem 97: 1-17.
13. Golub TR, Barker GF, Bohlander SK, Hiebert SW, Ward DC, Bray-Ward P, Morgan E, Raimondi SC, Rowley JD, Gilliland DG. 1995. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci USA 92: 4917-4921.
14. Gorczynski MJ, Grembecka J, Zhou Y, Kong Y, Roudaia L, Douvas MG, Newman M, Bielnicka I, Baber G, Corpora T, Shi J, Sridharan M, Lilien R, Donald BR, Speck NA, Brown ML, Bushweiler JH. 2007. Allosteric inhibition of the protein-protein interaction between the leukemia-associated proteins Runx1 and CBFbeta. Chem Biol 14: 1186-1197.
15. Hajra A, Collins FS. 1995. Structure of the leukemia-associated human CBFB gene. Genomics 26: 571-579.
16. Hiebert SW, Sun W, Davis JN, Golub T, Shurtleff S, Buijs A, Downing JR, Grosveld G, Roussell MF, Gilliland DG, Lenny N, Meyers S. 1996. The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription. Mol Cell Biol 16: 1349-1355.
17. Huang X, Peng JW, Speck NA, Bushweller JH. 1999. Solution structure of core binding factor beta and map of the CBF alpha binding site. Nat Struct Biol 6: 624-627.
18. Huang G, Shigesada K, Ito K, Wee HJ, Yokomizo T, Ito Y. 2001. Dimerization with PEBP2beta protects RUNX1/AML1 from ubiquitin-proteosome-mediated degradation. EMBO J 20: 723-733.
19. Ito Y. 2004. Oncogenic potential of the RUNX gene family: 'Overview'. Oncogene 23: 4198-4208.
20. Koeneman KS, Yeung F, Chung LW. 1999. Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 39: 246-261.
21. Komori T. 2003. Requisite roles of Runx2 and Cbfb in skeletal development. J Bone Miner Metab 21: 193-197.
22. Kundu M, Javed A, Jeon JP, Horner A, Shum L, Eckhaus M, Muenke M, Lian JB, Yang Y, Nuckolls GH, Stein GS, Liu PP. 2002. Cbfbeta interacts with Runx2 and has a critical role in bone development. Nat Genet 32: 639-644.
23. Levanon D, Groner Y. 2004. Structure and regulated expression of mammalian RUNX genes. Oncogene 23: 4211-4219.
24. Levanon D, Negreanu V, Bernstein Y, Bar-Am I, Avivi L, Groner Y. 1994. AML1, AML2, and AML3, the human members of the runt domain gene-family: cDNA structure, expression, and chromosomal location. Genomics 23: 425-432.
25. Lever AM, Kaye JF, McCann E, Chadwick D, Dorman N, Thomas J, Zhao J. 1999. Lentivirus vectors for gene therapy. Biochem Soc Trans 27: 841-847.
26. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, Kim HM, Kim WJ, Yamamoto H, Yamashita N, Yano T, Ikeda T, Itohara S, Inazawa J, Abe T, Hagiwara A, Yamagishi H, Ooe A, Kaneda A, Sugimura T, Ushijima T, Bae SC, Ito Y. 2002. Casual relationship between the loss of RUNX3 expression and gastric cancer. Cell 109: 113-124.
27. Lin DL, Tarnowski CP, Zhang J, Dai J, Rohn E, Patel AH, Morris MD, Keller ET. 2001. Bone metastaic LNVaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 47: 212-221.
28. Liu P, Tarle SA, Hajra A, Claxton DF, Marlton P, Freedman M, Siciliano MJ, Collins FS. 1993. Fusion between transcirption factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science 261: 1041-1044.
29. Look AT. 1997. Oncogenic transcription factors in the human acute leukemias. Science 278: 1059-1064.
30. Lutterbach B, Hou Y, Durst KL, Hiebert SW. 1999. The inv(16) encodes an acute myeloid leukemia 1 transcriptional corepressor. Proc Natl Acad Sci USA 96: 12822-12827.
31. Mallo M, Espinet B, Salido M, Ferrer A, Pedro C, Besses C, Perez-Vila E, Serrano S, Florensa L, Sole F. 2007. Gain of multiple copies of the CBFB gene: A new genetic aberration in a case of granulocytic sarcoma. Cancer Genet Cytogenet 179: 62-65.
32. Meyers S, Downing JR, Hiebert SW. 1993. Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA binding proteins: The runt homology domain is required for DNA binding and protein-protein interactions. Mol Cell Biol 13: 6336-6345.
33. Meyers S, Lenny N, Hiebert SW. 1995. The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol Cell Biol 15: 1974-1982.
34. Michaud J, Wu F, Osato M, Cottles GM, Yanagida M, Asou N, Shigesada K, Ito Y, Benson KF, Raskind WH, Rossier C, Antonarakis SE, Israels S, McNicol A, Weiss HM, Scott HS. 2002. In vitro analysis of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: Implications for mechanisms of pathogenesis. Blood 99: 1364-1372.
35. Minelli A, Maserati E, Rossi G, Bernardo ME, De Stefano P, Cecchini MP, Valli R, Albano V, Pierani P, Leszl A, Sainati L, Lo Curto F, Danesino C, Locatelli F, Pasquali F. 2004. Familial platelet disorder with propensity to acute myelogenous leukemia: Genetic heterogeneity and progression to leukemia via acquisition of clonal chromosome anomalies. Genes Chromosomes Cancer 40: 165-171.
36. Miyoshi H, Shimizu K, Kozu T, Maseki N, Kaneko Y, Ohki M. 1991. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci USA 88: 10431-10434.
37. Miyoshi H, Kozu T, Shimizu K, Enomoto K, Maseki N, Kaneko Y, Kamada N, Ohki M. 1993. The t(8;21) translocation in acute myeloid leukemia results in production of an AML-1-MTG8 fusion transcript. EMBO J 12: 2715-2721.
38. Nevadunsky NS, Barbieri JS, Kwong J, Merritt MA, Welch WR, Berkowitz RS, Mok SC. 2009. RUNX3 protein is overexpressed in human epithelial ovarian cancer. Gynecol Oncol 112: 325-330.
39. Niini T, Kanerva J, Vettenranta K, Saarinen-Pihkala UM, Knuutila S. 2000. AML1 gene amplification: A novel finding in childhood acute lymphoblastic leukemia. Haematologica 85: 362-366.
40. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. 1996. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84: 321-330.
41. Orlichenko LS, Radisky DC. 2008. Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development. Clin Exp Metastasis 25(6): 593-600.
42. Osato M, Asou N, Abdalla E, Hoshino K, Yamasaki H, Okubo T, Suzushima H, Takatsuki K, Kanno T, Shigesada K, Ito Y. 1999. Biallelic and hetozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. Blood 93: 1817-1824.
43. Osato M, Yanagida M, Shigesada K, Ito Y. 2001. Point mutations of the RUNx1/AML1 gene in sporadic and familial myeloid leukemias. Int J Hematol 74: 245-251.
44. Paredes R, Arriagada G, Cruzat F, Olate J, Van Wijnen A, Lian J, Stein G, Stein J, Montecino M. 2004. The Runx2 transcription factor plays a key role in the 1alpha, 25-dihydroxy vitamin D3-dependent upregulation of the rat osteocalcin (OC) gene expression in osteoblastic cells. J Steroid Biochem Mol Biol 89-90: 269-271.
45. Planaguma J, Diaz-Fuertes M, Gil-Moreno A, Abal M, Monge M, Garcia A, Baro T, Thomson TM, Xercavins J, Alameda F, Reventos J. 2004. A differential gene expression profile reveals overexpression of RUNX1 in invasive endometrioid carcinoma. Cancer Res 64: 8846-8853.
46. Pratap J, Javed A, Languino LR, van Wijnen AJ, Stein JL, Stein GS, Lian JB. 2005. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol 25: 8581-8591.
47. Pratap J, Lian JB, Javed A, Barnes GL, van Wijnen AJ, Stein JL, Stein GS. 2006. Regulatory roles for Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev 25: 589-600.
48. Preudhomme C, Warot-Loze D, Roumier C, Grardel-Duflos N, Garand R, Lai JL, Dastugue N, Macintyre E, Denis D, Bauters F, Kerckaert JP, Cosson A, Fenaux P. 2000. High incidence of biallelic point mutations in the Runt domain of the AML1/PEBp2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood 96: 2862-2869.
49. Robertson AJ, Dickey-Sims C, Ransick A, Rupp DE, McCarthy JJ, Coffman JA. 2006. CBFbeta is a facultative Runx partner in the sea urchin embryo. BMC Biol 4: 4.
50. Roudaia L, Cheney MD, Manuylova E, Chen W, Morrow M, Park S, Lee CT, Kaur P, Williams D, Bushweller JH, Speck NA. 2009. CBFbeta is critical for AML1-ETO and TEL-AML1 activity. Blood 113: 3070-3079.
51. Salto-Tellez M, Peh BK, Ito K, Tan SH, Chong PY, Han HC, Tada K, Ong WY, Soong R, Voon DC, Ito Y. 2006. RUNX3 protein is overexpressed in human basal cell carcinomas. Oncogene 25: 7646-7649.
52. Speck NA. 2001. Core binding factor and its role in normal hematopoietic development. Curr Opin Hematol 8: 192-196.
53. Speck NA, Gilliland DG. 2002. Core-binding factors in hematopoiesis and leukaemia. Nat Rev Cancer 2: 502-513.
54. Waki T, Tamura G, Sato M, Terashima M, Nishizuka S, Motoyama T. 2003. Promoter methylation status of DAP-kinase and RUNX3 genes in neoplastic and non-neoplastic gastric epithelia. Cancer Sci 94: 360-364.
55. Wang S, Wang Q, Crute BE, Melnikova IN, Keller SR, Speck NA. 1993. Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor. Mol Cell Biol 13: 3324-3339.
56. Wang Q, Stacy T, Miller JD, Lewis AF, Gu TL, Huang X, Bushweller JH, Bories JC, Alt FW, Ryan G, Liu PP, Wynshaw-Boris A, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. 1996. The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo. Cell 87: 697-708.
57. Yeung F, Law WK, Yeh CH, Westendorf JJ, Zhang Y, Wang R, Kao C, Chung LW. 2002. Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells. J Biol Chem 277: 2468-2476.
58. Yoshida CA, Furuichi T, Fujita T, Fukuyama R, Kanatani N, Kobayashi S, Satake M, Takada K, Komori T. 2002. Core-binding factor beta interacts with Runx2 and is required for skeletal development. Nat Genet 32: 633-638.
59. Zhang S, Wei L, Zhang A, Zhang L, Yu H. 2009. RUNX3 gene methylation in epithelial ovaraian cancer tissues and ovarian cancer cell lines. Omics 13: 307-311.